These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 21953353)

  • 21. Statistical methods for a phase II oncology trial with a growth modulation index (GMI) endpoint.
    Kovalchik S; Mietlowski W
    Contemp Clin Trials; 2011 Jan; 32(1):99-107. PubMed ID: 20920605
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A sensitivity analysis of a randomized controlled trial of zinc in treatment of falciparum malaria in children.
    Fox MP; Lash TL; Hamer DH
    Contemp Clin Trials; 2005 Jun; 26(3):281-9. PubMed ID: 15911462
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical attrition due to biased preclinical assessments of potential efficacy.
    Lindner MD
    Pharmacol Ther; 2007 Jul; 115(1):148-75. PubMed ID: 17574680
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense?
    Dodd LE; Korn EL; Freidlin B; Jaffe CC; Rubinstein LV; Dancey J; Mooney MM
    J Clin Oncol; 2008 Aug; 26(22):3791-6. PubMed ID: 18669467
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of change in the presence of informative censoring: application to a longitudinal clinical trial of progressive renal disease.
    Schluchter MD; Greene T; Beck GJ
    Stat Med; 2001 Apr; 20(7):989-1007. PubMed ID: 11276031
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sample size determination for comparing several survival curves with unequal allocations.
    Halabi S; Singh B
    Stat Med; 2004 Jun; 23(11):1793-815. PubMed ID: 15160409
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Racial disparities among clinical research investigators.
    Getz K; Faden L
    Am J Ther; 2008; 15(1):3-11. PubMed ID: 18223347
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survival end point reporting in randomized cancer clinical trials: a review of major journals.
    Mathoulin-Pelissier S; Gourgou-Bourgade S; Bonnetain F; Kramar A
    J Clin Oncol; 2008 Aug; 26(22):3721-6. PubMed ID: 18669458
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Joint modeling of progression-free survival and death in advanced cancer clinical trials.
    Dejardin D; Lesaffre E; Verbeke G
    Stat Med; 2010 Jul; 29(16):1724-34. PubMed ID: 20572123
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Applications of a parametric model for informative censoring.
    Siannis F
    Biometrics; 2004 Sep; 60(3):704-14. PubMed ID: 15339293
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of a medication control officer to reduce bias in a clinical trial: lessons learned from the scleroderma lung study.
    Hsu VM; Khanna D; Smith E; Filemon T; Whelton S; Lopata M; Davis JC; Polito A; Heck L; Molitor J; Abeles M; Granda J; Korn J; Clements P;
    Clin Trials; 2010 Feb; 7(1):85-9. PubMed ID: 20032002
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Screening for disease: making evidence-based choices.
    Fields MM; Chevlen E
    Clin J Oncol Nurs; 2006 Feb; 10(1):73-6. PubMed ID: 16482730
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Last-observation-carried-forward imputation method in clinical efficacy trials: review of 352 antidepressant studies.
    Woolley SB; Cardoni AA; Goethe JW
    Pharmacotherapy; 2009 Dec; 29(12):1408-16. PubMed ID: 19947800
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Designing phase II studies in cancer with time-to-event endpoints.
    Owzar K; Jung SH
    Clin Trials; 2008; 5(3):209-21. PubMed ID: 18559409
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pemetrexed in malignant pleural mesothelioma.
    Hazarika M; White RM; Booth BP; Wang YC; Ham DY; Liang CY; Rahman A; Gobburu JV; Li N; Sridhara R; Morse DE; Lostritto R; Garvey P; Johnson JR; Pazdur R
    Clin Cancer Res; 2005 Feb; 11(3):982-92. PubMed ID: 15709163
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Local Investigators Significantly Overestimate Overall Response Rates Compared to Blinded Independent Central Reviews in Phase 2 Oncology Trials.
    Dello Russo C; Cappoli N; Pilunni D; Navarra P
    J Clin Pharmacol; 2021 Jun; 61(6):810-819. PubMed ID: 33244770
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of risk of bias in randomized clinical trials in surgery.
    Gurusamy KS; Gluud C; Nikolova D; Davidson BR
    Br J Surg; 2009 Apr; 96(4):342-9. PubMed ID: 19283747
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of informative censoring on the Kaplan-Meier estimate of progression-free survival in phase II clinical trials.
    Campigotto F; Weller E
    J Clin Oncol; 2014 Sep; 32(27):3068-74. PubMed ID: 25113767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.